Advanced Clinical Trial Workshops in China (ACT China)

Clinical trials play a vital role in improving outcomes for cancer patients. In 2011, the combined forces of CSCO and STO, with faculty support from the U.S. Food and Drug Administration (FDA), European Medicine Agency (EMA), and American Society of Clinical Oncology (ASCO), created and conducted Advanced Clinical Trial Workshops in China (ACT China), developed a clinical trial curriculum covering ethics, preclinical studies, clinical trial design/conduct, statistics, and regulatory considerations. During these meetings, a global faculty of experts addressed current issues and challenges in executing phase I, II, and III clinical trials, through a series of lectures, discussions, and workshops.

The curriculum was designed by an international steering committee of experts from CSCO, FDA, EMA and ASCO to help transform oncology research in China for the benefit of cancer patients in China and around the world.

ACT 2011


Program Book PDFs Below

ACT China I

Program PDF

November 18-20,  2011
Rose Manor, Taicang (Shanghai)

ACT China II

Program PDF

November 30 - December 2, 2012
The Vanburgh Hotel, Guangzhou


Program PDF

November 22 - 24, 2013
Hilton Baiyun Hotel, Guangzhou

ACT China IV

Program PDF

November 21-23, 2014
Hilton Shenzhen Shekou Nanhai

Privacy Policy | Terms of Use | Contact Us

Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization.